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treatment). Thus, although the results of the Honeypot 
study1 show the eﬃ  cacy of mupirocin versus Medihoney, 
the important question of whether patients with a 
healthy catheter exit site for peritoneal dialysis should 
receive prophylactic treatment remains to be addressed. 
In our view, and according to the principle of primum 
non nocere (ﬁ rst do no harm), the key to preservation 
of exit-site integrity is optimal catheter ﬁ xation and 
avoidance of unnecessary manipulations. We realise, 
however, that this approach of let nature do the work 
is diﬃ  cult to assess in a randomised controlled trial and 
probably not endorsed in modern medicine.
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Antimicrobial resistance in intensive care units
More than two-thirds of cases of ICU-acquired 
bacteraemia are caused by multidrug-resistant or 
extensively drug-resistant bacteria.1 Although the 
prevalence of meticillin-resistant Staphylococcus aureus 
is decreasing, glycopeptide-resistant enterococci, 
extended-spectrum β-lactamase-producing Entero-
bacteriaceae, and Gram-negative bacteria resistant to 
carbapenems have become a cause for concern.2 The 
eﬀ ectiveness of universal strategies based on hand 
hygiene and decolonisation or active surveillance culture 
and contact precautions for the control of multidrug-
resistant bacteria in ICUs is unclear. 
Active surveillance with contact precautions for 
carriers was eﬀ ective for controlling meticillin-resistant 
S aureus in one study3 but not in another,4 despite 
use of similar interventions. However, the negative 
study had several ﬂ aws,4 whereas the other was quasi-
experimental, with other interventions possibly 
accounting for the eﬀ ect.3 Universal decolonisation 
with chlorhexidine body-washing—with5 or without6 
nasal mupirocin—can decrease acquisition of 
meticillin-resistant S aureus and glycopeptide-resistant 
enterococci, with some reduction in infections. These 
studies raised more questions than they answered, 
did not address the spread of resistant Gram-
negative bacteria, and collected, at best, incomplete 
data for compliance with hand hygiene and contact 
precautions. 
In The Lancet Infectious Diseases, Lennie Derde and 
colleagues7 report a sophisticated and ambitious 
study, with epidemiological and statistical analysis 
of 13 European ICUs, involving almost 9000 patients 
and more than 40 000 hand-hygiene opportunities. 
The researchers aimed to answer two major questions. 
Should we use a universal approach—ie, improving hand 
hygiene and chlorhexidine body-washing or a strategy 
of active surveillance with contact precautions for 
carriers? And which bacteria will be aﬀ ected? 
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The acquisition rate of extended-spectrum β lacta-
mase-producing Enterobacteriaceae (n=1966) was 
much higher than that of vancomycin-resistant 
enterococci (n=346) or meticillin-resistant S aureus 
(n=508). The universal strategy was eﬀ ective for 
controlling meticillin-resistant S aureus with no 
additional eﬃ  cacy from active surveillance with contact 
precautions. But no reduction occurred with any type 
of intervention for highly resistant Enterobacteriaceae 
(mostly extended-spectrum β lactamase-producing 
Enterobacteriaceae) despite an impressive hand-
hygiene compliance of 77%.
How can we explain the failure to control extended-
spectrum β lactamase-producing Enterobacteriaceae? 
First, 77% compliance might not be high enough in 
view of the high prevalence of extended-spectrum 
β lactamase-producing Enterobacteriaceae at admission, 
the high colonisation pressure, and the ease of cross-
transmission. However, higher compliance would be very 
diﬃ  cult to achieve, perhaps impossible, in routine clinical 
practice. 
Second, some factors that drive the spread of 
extended-spectrum β lactamase-producing Entero-
bacteriaceae were not taken into account, such as other 
routes of transmission and the role of antimicrobial 
selective pressure. Indeed, mathematical modelling 
suggested diﬀ erences in the predominant routes of 
acquisition of diﬀ erent multidrug-resistant bacteria, 
with highly resistant Enterobacteriaceae possibly 
originating from an endogenous source, whereas 
meticillin-resistant S aureus is predominantly acquired 
through cross-transmission.8 Finally, diﬀ erent epi-
demiological features at each centre could be a result of 
levels of compliance with the prevention programme, in 
addition to compliance with hand hygiene. 
The combined eﬀ ect of improving hand hygiene 
and chlorhexidine body-washing helped to control 
meticillin-resistant S aureus, but which part of the 
intervention was eﬀ ective is unclear. Other studies 
suggest that universal chlorhexidine body-washing can 
control transmission of meticillin-resistant S aureus and 
glycopeptide-resistant enterococci.6,9,10 Anecdotally, 
chlorhexidine body-washing was not eﬀ ective for 
control of highly resistant Enterobacteriaceae.
Active surveillance by culture with contact precautions 
for carriers of meticillin-resistant S aureus identiﬁ ed 
either by conventional or rapid PCR screening had no 
incremental eﬀ ect on acquisition. The cost-beneﬁ t 
balance of isolating ICU patients is still controversial,11,12 
and this result raises many methodological questions 
that need to be answered before contact isolation is 
abandoned. Active surveillance with contact precautions 
was added in the third phase of the study, but was done 
in several ICUs during the ﬁ rst two phases. Moreover, 
compliance with contact isolation was not assessed. 
Because only 18% of rooms were single, contact 
isolation precaution might have been diﬃ  cult to 
implement immediately. All rooms in new ICUs should 
be single rooms.13 Finally, the lack of contribution of 
active surveillance with contact precautions might be 
partly explained by the high hand-hygiene compliance. 
In conclusion, this pragmatic study provides important 
evidence for systematically including hand-hygiene 
strategies in any programme to control multidrug-
resistant bacteria. The absence of an eﬀ ect on antibiotic-
resistant Gram-negative bacteria is worrisome. Strategies 
to prevent overgrowth of endogenous ﬂ ora—such 
as selective digestive decontamination—should be 
investigated14 although results of preliminary studies are 
unclear.15 Methods to reduce antibiotic selection pressure 
should also be explored. 
Jean-Ralph Zahar, Jean-Christophe Lucet, 
*Jean-François Timsit
Decision Sciences in Infectious Disease Prevention, Control and 
Care, UMR 1137 Paris Diderot University, Sorbonne, Paris, France 
(J-RZ, J-CL J-FT); Angers University–Angers Hospital, Angers, 
France (J-RZ); Infection Control Unit, Bichat–Claude Bernard 
Hospital, Assistance Publique–Hôpitaux de Paris, Paris Diderot 
University, Sorbonne, Paris, France (J-CL); and Medical and 
Infectious Diseases Intensive Care Unit, Bichat University Hospital, 
Paris Diderot University, Paris 75018, France (J-FT)
jean-francois.timsit@bch.aphp.fr
We declare that we have no conﬂ icts of interest.
1 Tabah A, Koulenti D, Laupland K, et al. Characteristics and determinants of 
outcome of hospital-acquired bloodstream infections in intensive care 
units: the EUROBACT International Cohort Study. Intensive Care Med 2012; 
38: 1930–45.
2 Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the 
global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 
2013; 13: 785–96.
3 Jain R, Kralovic SM, Evans ME, et al. Veterans Aﬀ airs initiative to prevent 
methicillin-resistant Staphylococcus aureus infections. N Engl J Med 2012; 
364: 1419–30.
4 Huskins WC, Huckabee CM, O’Grady NP, et al. Intervention to reduce 
transmission of resistant bacteria in intensive care. N Engl J Med 2012; 
364: 1407–18.
5 Huang SS, Septimus E, Kleinman K, et al. Targeted versus universal 
decolonization to prevent ICU infection. N Engl J Med 2013; 368: 2255–65.
6 Climo MW, Yokoe DS, Warren DK, et al. Eﬀ ect of daily chlorhexidine bathing 
on hospital-acquired infection. N Engl J Med 2013; 368: 533–42.
Comment
www.thelancet.com/infection   Vol 14   January 2014 5
7 Derde LPG, Cooper BS, Goosens H, et al. Interventions to reduce 
colonisation and transmission of antimicrobial-resistant bacteria in 
intensive care units: an interrupted time series study and cluster 
randomised trial. Lancet Infect Dis 2013; published online Oct 23. http://dx.
doi.org/10.1016/S1473-3099(13)70295-0.
8 Bootsma MC, Bonten MJ, Nijssen S, Fluit AC, Diekmann O. An algorithm to 
estimate the importance of bacterial acquisition routes in hospital settings. 
Am J Epidemiol 2007; 166: 841–51.
9 Derde LP, Dautzenberg MJ, Bonten MJ. Chlorhexidine  body-washing to 
control antimicrobial-resistant bacteria in intensive care units: a systematic 
review. Intensive Care Med 2012; 38: 931–39.
10 Huang SS, Septimus E, Kleinman K, et al. Targeted versus universal 
decolonization to prevent ICU infection. N Engl J Med 2013; 368: 2255–65.
11 Zahar JR, Garrouste-Orgeas M, Vesin A, et al. Impact of contact isolation for 
multidrug-resistant organisms on the occurrence of medical errors and 
adverse events. Intensive Care Med 2013; published online August. http://
dx.doi.org/10.1007/s00134-013-3071-0.
12 Morgan DJ, Pineles L, Shardell M, et al. The eﬀ ect of contact precautions on 
healthcare worker activity in acute care hospitals. Infect Control Hosp Epidemiol 
2013; 34: 69–73.
13 Rhodes A, Moreno RP, Azoulay E, et al. Prospectively deﬁ ned indicators to 
improve the safety and quality of care for critically ill patients: a report 
from the Task Force on Safety and Quality of the European Society of 
Intensive Care Medicine (ESICM). Intensive Care Med 2012; 38: 598–605.
14 Silvestri L, de la Cal MA, van Saene HK. Selective decontamination of the 
digestive tract: the mechanism of action is control of gut overgrowth. 
Intensive Care Med 2012; 38: 1738–50.
15 Saidel-Odes L, Polachek H, Peled N, et al. A randomized, double-blind, 
placebo-controlled trial of selective digestive decontamination using oral 
gentamicin and oral polymyxin E for eradication of carbapenem-resistant 
Klebsiella pneumoniae carriage. Infect Control Hosp Epidemiol 2012; 33: 14–19.
The HIV care cascade through time
HIV care and treatment can prevent morbidity, 
mortality, and virus transmission. Optimum care for 
individuals and communities of people living with 
HIV involves identiﬁ cation of infected individuals, 
linkage to initial HIV care, long-term retention in care, 
and treatment adherence—the so-called cascade of 
care.1 However, in many settings, the scope of the 
cascade is such that few patients actually achieve 
undetectable viral loads, the end goal of engagement 
in care. Understanding how to measure and intervene 
to improve engagement in HIV care is a subject of 
intense debate.
In The Lancet Infectious Diseases, Bohdan Nosyk and 
colleagues2 from the STOP HIV/AIDS Study Group chart 
the longitudinal changes in the cascade of HIV care in 
British Columbia, Canada, from 1996 to 2011. Their 
study is the ﬁ rst longitudinal examination of the HIV 
care cascade. The investigators assessed the numbers 
and proportions of individuals in eight distinct stages 
of the cascade: HIV infected, diagnosed, linked to HIV 
care, retained in care, antiretroviral treatment indicated, 
receiving antiretroviral treatment, adherent to 
antiretroviral treatment, and virologically suppressed.
The study’s strengths derive from the extensive use 
of comprehensive linked databases from national and 
provincial health programmes, and population-based 
registries from the BC Centre of Excellence in HIV/AIDS 
(Vancouver, BC, Canada)—the sole provincial agency 
providing HIV diagnostic testing and distribution of all 
antiretroviral drugs. Additional information was derived 
from provincial hospital, pharmacy, and vital statistics 
databases. The analysis shows that overall engagement 
in care and use of antiretroviral treatment improved 
between 1996 and 2011, but that substantial numbers 
of individuals are still lost from each step of the cascade. 
In 2011, an estimated 29% of HIV-infected individuals 
remained undiagnosed, an additional 4–10% were not 
linked to HIV care, and another 20% were not retained 
in care. Overall, viral suppression increased from 1% 
to 35% of the HIV-infected population over the study 
period.
Nosyk and colleagues’ study shows us the value of 
looking longitudinally at the use of HIV care. Although 
changing standards for when to begin antiretroviral 
treatment limit the ability to analyse trends in 
viral suppression over time, increasing numbers of 
individuals are achieving this important benchmark. 
However, only a minority of HIV-infected individuals 
in British Columbia are virologically suppressed, and 
this ﬁ nding is surprising and disappointing. As the 
investigators suggest, emigration from the province 
might account for some losses to follow-up; in a recent 
US study,3 about 15% of individuals emigrated from the 
state in which they were diagnosed during 3–5 years 
of follow-up. Other potential losses of data in British 
Columbia, such as receiving care through participation 
in clinical trials, seem to have had little eﬀ ect on 
estimates of viral suppression.
The implications of persistent gaps in cascade steps 
before administration of antiretroviral treatment and 
viral suppression are particularly worrying. Compared 
with research from the USA,1,4 the investigators in 
British Columbia report fairly similar proportions of HIV 
underdiagnosis, linkage to care, and retention in care. 
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